Paragraph IV is supposed to be the clean, chess-like play in generic drug strategy: challenge the patent, win the exclusivity battle, and move faster than the brand. But the realityespecially in 2025is that brands increasingly design around the rules o…

The 180-Day Exclusivity Trap: Why First Filer Wins on PaperBut Loses in the Real World
In generic and biosimilar drug development, the first filer rule is supposed to feel like a cheat code.
File early, trigger 180 days of exclusivity, capture market s…

Stop Chasing Blockbusters: The High-Margin World of Unloved Orphan Drug Patents
Most pharmaceutical conversations startand endat the same place: blockbuster revenue projections, peak sales curves, and late-stage pipeline decks. Investors want the next …

Your regulatory team should not treat patents like an afterthought.
Agonizingly common scenario: a strategy meeting focused on label language, PMRs, launch timelinesand then, somewhere down the line, a patent notice lands on the legal desk like a meteo…

Drug patent intelligence cant be a late-stage checkbox. It has to be a starting line decision.
Theres a familiar pattern in life sciences: the R&D program moves fast, the science gets validated, budgets expand, and thensometimes years insomeone ask…

Ever notice how people talk about biosimilars like the hard part is proving theyre the same?
That partbioequivalenceis undeniably important. But if youre building a biologics strategy, you quickly learn the truth: bioequivalence is often the easy part….

Pharma doesnt win by having the most patents. It wins by having the right ones at the right cost.
Theres a seductive idea making the rounds in IP circles: Just file enough to keep the portfolio safe. Minimal filings. Low immediate spend. A lighter lift…

A single paragraph can cost $50 million. Heres what a bad Paragraph IV filing actually changed for a generic drugmaker.
If youve spent any time around generic competition, you know the narrative: Paragraph IV certifications are about diligence, speed, …

🚨 The pharma launch calendar is changingand the math is driving it.
In patent litigation, companies often treat outcomes like weather: wait, watch, prepare, and hope the storm doesnt hit your launch date. But what if your launch decision isnt primar…

Evergreening isnt a conspiracyits a pattern. Heres how to spot the cracks in a 20‑patent thicket.
The pharmaceutical industry is built on timelines: filing, approvals, exclusivity, andeventuallycompetition. But in the real world, competition is often…